![]() |
Name |
Hillone
|
Molecular Formula | C15H20O3 | |
IUPAC Name* |
2,2,6,6,8,8-hexamethylchromene-5,7-dione
|
|
SMILES |
CC1(C=CC2=C(O1)C(C(=O)C(C2=O)(C)C)(C)C)C
|
|
InChI |
InChI=1S/C15H20O3/c1-13(2)8-7-9-10(16)14(3,4)12(17)15(5,6)11(9)18-13/h7-8H,1-6H3
|
|
InChIKey |
YZAAUZMWCZGKMQ-UHFFFAOYSA-N
|
|
Synonyms |
Hillone
|
|
CAS | NA | |
PubChem CID | 85714133 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 248.32 | ALogp: | 2.7 |
HBD: | 0 | HBA: | 3 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 43.4 | Aromatic Rings: | 2 |
Heavy Atoms: | 18 | QED Weighted: | 0.615 |
Caco-2 Permeability: | -4.79 | MDCK Permeability: | 0.00002760 |
Pgp-inhibitor: | 0.949 | Pgp-substrate: | 0.004 |
Human Intestinal Absorption (HIA): | 0.12 | 20% Bioavailability (F20%): | 0.823 |
30% Bioavailability (F30%): | 0.158 |
Blood-Brain-Barrier Penetration (BBB): | 0.027 | Plasma Protein Binding (PPB): | 81.25% |
Volume Distribution (VD): | 2.14 | Fu: | 18.95% |
CYP1A2-inhibitor: | 0.08 | CYP1A2-substrate: | 0.623 |
CYP2C19-inhibitor: | 0.554 | CYP2C19-substrate: | 0.859 |
CYP2C9-inhibitor: | 0.072 | CYP2C9-substrate: | 0.19 |
CYP2D6-inhibitor: | 0.312 | CYP2D6-substrate: | 0.109 |
CYP3A4-inhibitor: | 0.286 | CYP3A4-substrate: | 0.87 |
Clearance (CL): | 3.737 | Half-life (T1/2): | 0.567 |
hERG Blockers: | 0.001 | Human Hepatotoxicity (H-HT): | 0.84 |
Drug-inuced Liver Injury (DILI): | 0.954 | AMES Toxicity: | 0.013 |
Rat Oral Acute Toxicity: | 0.169 | Maximum Recommended Daily Dose: | 0.081 |
Skin Sensitization: | 0.256 | Carcinogencity: | 0.927 |
Eye Corrosion: | 0.013 | Eye Irritation: | 0.109 |
Respiratory Toxicity: | 0.966 |